Optimized Nanostructured Lipid Carriers for Dutasteride Delivery: Improving Therapeutic Efficiency and Minimizing Adverse Effects

The study developed optimized nanostructured lipid carriers (NLCs) for delivering dutasteride to improve therapeutic efficiency and reduce side effects. The formulation achieved an 81% entrapment efficiency, a particle size of 109.3 nm, and a zeta potential of -37.5 MV. In vitro tests showed that DUT-NLCs were more effective than the pure drug in targeting cancer cells, suggesting significant anticancer benefits and potential for reducing adverse effects with lower dosages. Stability testing over 90 days confirmed the robustness of the formulation, indicating its potential for enhanced delivery and efficacy in clinical settings.